Literature DB >> 2974204

An overview of the use of the monoclonal antibody OKT3 in renal transplantation.

D J Norman1.   

Abstract

The murine monoclonal anti-T cell antibody, OKT3, has been used during the past 6 years in various clinical transplantation studies. Undoubtedly it has proved to be the most effective and specific immunosuppressive drug widely available for use in organ transplantation. However, because of problems of first-dose symptoms, recurrent rejection, and antibody production, currently used protocols with OKT3 might not be the final answer in immunosuppressive therapy. OKT3 is an important prototype of future monoclonal antibodies and can be considered the gold standard against which newer drugs must be compared.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974204

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

Review 1.  Renal transplantation.

Authors:  R S Trompeter
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

2.  An adapted consensus protein design strategy for identifying globally optimal biotherapeutics.

Authors:  Yanyun Liu; Kenny Tsang; Michelle Mays; Gale Hansen; Jeffrey Chiecko; Maureen Crames; Yangjie Wei; Weijie Zhou; Chase Fredrick; James Hu; Dongmei Liu; Douglas Gebhard; Zhong-Fu Huang; Akshita Datar; Anthony Kronkaitis; Kristina Gueneva-Boucheva; Daniel Seeliger; Fei Han; Saurabh Sen; Srinath Kasturirangan; Justin M Scheer; Andrew E Nixon; Tadas Panavas; Michael S Marlow; Sandeep Kumar
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

Review 3.  mRNA as novel technology for passive immunotherapy.

Authors:  Thomas Schlake; Andreas Thess; Moritz Thran; Ingo Jordan
Journal:  Cell Mol Life Sci       Date:  2018-10-17       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.